Firategrast

Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity[1][2][3].

Product Specifications

CAS Number

[402567-16-2]

Product Name Alternative

SB 683699

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Integrin

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Firategrast.html

Purity

99.75

Solubility

DMSO : ≥ 100 mg/mL|Ethanol : ≥ 50 mg/mL

Smiles

O=C(O)[C@@H](NC(C1=C(F)C=CC=C1F)=O)CC2=CC=C(C3=C(OC)C=C(COCC)C=C3OC)C=C2

Molecular Formula

C27H27F2NO6

Molecular Weight

499.50

Precautions

H302, H315, H319, H335

References & Citations

[1]Moses O. Evbuomwan, et al. Generation and Characterization of Novel VLA-4 Inhibitors for Stem Cell Mobilization in Combination with a CXCR2 Agonist. Blood (2017) 130 (Supplement 1) : 3197.|[2]Sarah E M Herman, et al. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. Clin Cancer Res. 2015 Oct 15;21 (20) :4642-51.|[3]Eva Szenes, et al. TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. Leukemia. 2020 Sep;34 (9) :2498-2502.|[4]H Rahimi, et al. Aberrant regulation of the integrin very late antigen-4 in systemic lupus erythematosus. Lupus. 2013 Mar;22 (3) :297-306.